AP3681A - Modified release formulations for oprozomib - Google Patents
Modified release formulations for oprozomibInfo
- Publication number
- AP3681A AP3681A AP2015008387A AP2015008387A AP3681A AP 3681 A AP3681 A AP 3681A AP 2015008387 A AP2015008387 A AP 2015008387A AP 2015008387 A AP2015008387 A AP 2015008387A AP 3681 A AP3681 A AP 3681A
- Authority
- AP
- ARIPO
- Prior art keywords
- oprozomib
- release formulations
- modified release
- modified
- formulations
- Prior art date
Links
- 108010064641 ONX 0912 Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title 1
- 229950005750 oprozomib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2015008387A0 AP2015008387A0 (en) | 2015-04-30 |
| AP3681A true AP3681A (en) | 2016-04-19 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2015008387A AP3681A (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (en:Method) |
| EP (1) | EP2912025A4 (en:Method) |
| JP (1) | JP6505604B2 (en:Method) |
| KR (1) | KR20150070406A (en:Method) |
| CN (1) | CN104968650A (en:Method) |
| AP (1) | AP3681A (en:Method) |
| AR (1) | AR093126A1 (en:Method) |
| AU (1) | AU2013334258A1 (en:Method) |
| BR (1) | BR112015008572A2 (en:Method) |
| CA (1) | CA2888039A1 (en:Method) |
| CL (1) | CL2015001085A1 (en:Method) |
| CR (1) | CR20150266A (en:Method) |
| EA (1) | EA201590797A1 (en:Method) |
| HK (2) | HK1215709A1 (en:Method) |
| IL (1) | IL238244A0 (en:Method) |
| IN (1) | IN2015DN03921A (en:Method) |
| MX (1) | MX2015005069A (en:Method) |
| PE (1) | PE20151051A1 (en:Method) |
| PH (1) | PH12015500823A1 (en:Method) |
| SG (1) | SG11201502849XA (en:Method) |
| TN (1) | TN2015000135A1 (en:Method) |
| TW (1) | TW201422255A (en:Method) |
| UY (1) | UY35091A (en:Method) |
| WO (1) | WO2014066681A1 (en:Method) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| CA2988918A1 (en) | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| CN109641860B (zh) | 2016-06-29 | 2024-05-28 | 科智生命科学公司 | 制备肽环氧酮免疫蛋白酶体抑制剂和其前体的方法 |
| JP2019529458A (ja) | 2016-09-21 | 2019-10-17 | 小野薬品工業株式会社 | オプロゾミブ用の即放性製剤 |
| US20180161279A1 (en) * | 2016-12-14 | 2018-06-14 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| JP2020533382A (ja) | 2017-09-14 | 2020-11-19 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 癌の組合せ治療 |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| EP4522183A2 (en) | 2022-05-11 | 2025-03-19 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070105786A1 (en) * | 2005-11-09 | 2007-05-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US20090105156A1 (en) * | 2007-10-04 | 2009-04-23 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| US20100240903A1 (en) * | 2009-03-20 | 2010-09-23 | Onyx Therapeutics, Inc. | Crystalline tripeptide epoxy ketone protease inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| HUP0303128A3 (en) * | 2001-02-12 | 2008-03-28 | Wyeth Corp | Novel succinate salt of o-desmethyl-venlafaxine, process for preparation thereof, its use and pharmaceutical composition containing it |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| EP1974725A4 (en) * | 2006-01-10 | 2012-12-05 | Kissei Pharmaceutical | PREPARATION WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
-
2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en active Application Filing
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070105786A1 (en) * | 2005-11-09 | 2007-05-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
| US20090105156A1 (en) * | 2007-10-04 | 2009-04-23 | Proteolix, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| US20100240903A1 (en) * | 2009-03-20 | 2010-09-23 | Onyx Therapeutics, Inc. | Crystalline tripeptide epoxy ketone protease inhibitors |
| US20120077855A1 (en) * | 2009-03-20 | 2012-03-29 | Pasit Phiasivongsa | Crystalline tripeptide epoxy ketone protease inhibitors |
| US20120088903A1 (en) * | 2009-03-20 | 2012-04-12 | Pasit Phiasivongsa | Crystalline tripeptide epoxy ketone protease inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015008572A2 (pt) | 2017-07-04 |
| HK1215709A1 (zh) | 2016-09-09 |
| IL238244A0 (en) | 2015-06-30 |
| PE20151051A1 (es) | 2015-08-03 |
| TN2015000135A1 (en) | 2016-10-03 |
| CL2015001085A1 (es) | 2015-08-28 |
| AU2013334258A1 (en) | 2015-04-30 |
| US20160213610A1 (en) | 2016-07-28 |
| HK1208222A1 (en) | 2016-02-26 |
| SG11201502849XA (en) | 2015-05-28 |
| EA201590797A1 (ru) | 2016-02-29 |
| JP6505604B2 (ja) | 2019-04-24 |
| CR20150266A (es) | 2015-08-14 |
| MX2015005069A (es) | 2015-07-17 |
| US20140113855A1 (en) | 2014-04-24 |
| AR093126A1 (es) | 2015-05-20 |
| JP2015535255A (ja) | 2015-12-10 |
| PH12015500823A1 (en) | 2015-06-22 |
| TW201422255A (zh) | 2014-06-16 |
| IN2015DN03921A (en:Method) | 2015-10-02 |
| AP2015008387A0 (en) | 2015-04-30 |
| EP2912025A1 (en) | 2015-09-02 |
| KR20150070406A (ko) | 2015-06-24 |
| UY35091A (es) | 2014-05-30 |
| WO2014066681A1 (en) | 2014-05-01 |
| CA2888039A1 (en) | 2014-05-01 |
| CN104968650A (zh) | 2015-10-07 |
| US9295708B2 (en) | 2016-03-29 |
| EP2912025A4 (en) | 2016-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500212B (en) | Progesterone formulations | |
| IL234256B (en) | Tamper resistant immediate release formulations | |
| RS59221B1 (sr) | Formulacije antitela | |
| ZA201509340B (en) | Proliposomal testosterone formulations | |
| IL236304A0 (en) | Formulations for diclofenac | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201503603B (en) | Composition for immediate and extended release | |
| AP3681A (en) | Modified release formulations for oprozomib | |
| GB201500511D0 (en) | Brake | |
| PT2908835T (pt) | Formulações estáveis | |
| GB201210530D0 (en) | Extended release formulations | |
| EP2840704A4 (en) | RETARDER | |
| GB201110278D0 (en) | Formulations | |
| GB201206178D0 (en) | Formulations | |
| IL220200A (en) | Release device | |
| HUP1100207A2 (en) | Modified release composition | |
| GB201213825D0 (en) | Damper-device for bouncing-device | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations |